Page 50 - Read Online

Page 14 of 14 Almeida et al. Vessel Plus 2021;5:44 https://dx.doi.org/10.20517/2574-1209.2021.66

73. Cantin L, Chartrand-Lefebvre C, Marcotte F, Pressacco J, Ducharme A, Lapierre C. Coronary artery noninvasive imaging in adult
Kawasaki disease. Clin Imaging 2009;33:181-7. DOI PubMed
74. van Dam LS, Dirikgil E, Bredewold EW, et al. Proteinase-3-anti-neutrophil cytoplasmic antibodies (PR3-ANCAs) predict relapses in
ANCA-associated vasculitis patients after rituximab. Nephrol Dial Transplant 2020:gfaa066. DOI PubMed
75. Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-
associated vasculitis. Arthritis Rheum 2012;64:3760-9. DOI PubMed
+
76. Bunch DO, McGregor JG, Khandoobhai NB, et al. Decreased CD5 B cells in active ANCA vasculitis and relapse after rituximab. Clin
J Am Soc Nephrol 2013;8:382-91. DOI PubMed PMC
77. Unizony S, Lim N, Phippard DJ, et al. Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis
Rheumatol 2015;67:535-44. DOI PubMed PMC
78. Bader L, Koldingsnes W, Nossent J. B-lymphocyte activating factor levels are increased in patients with Wegener’s granulomatosis
and inversely correlated with ANCA titer. Clin Rheumatol 2010;29:1031-5. DOI PubMed
79. Dolff S, Witzke O, Wilde B. Th17 cells in renal inflammation and autoimmunity. Autoimmun Rev 2019;18:129-36. DOI PubMed
80. von Borstel A, Lintermans LL, Heeringa P, et al. Circulating CD24hiCD38hi regulatory B cells correlate inversely with the ThEM17
cell frequency in granulomatosis with polyangiitis patients. Rheumatology (Oxford) 2019. DOI PubMed
81. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. A prospective
study in 117 patients. La Presse Médicale 2013;42:679. DOI
82. Li K, Zhang Y, Zhang Y, et al. Tyrosine kinase Fyn promotes osteoarthritis by activating the β-catenin pathway. Ann Rheum Dis
2018;77:935-43. DOI PubMed
83. Wang Y, Zhang S, Zhang N, et al. Reduced activated regulatory T cells and imbalance of Th17/activated Treg cells marks renal
involvement in ANCA-associated vasculitis. Mol Immunol 2020;118:19-29. DOI PubMed
84. Deng J, Wei Y, Fonseca VR, Graca L, Yu D. T follicular helper cells and T follicular regulatory cells in rheumatic diseases. Nat Rev
Rheumatol 2019;15:475-90. DOI PubMed
85. Gou SJ, Yuan J, Wang C, Zhao MH, Chen M. Alternative complement pathway activation products in urine and kidneys of patients
with ANCA-associated GN. Clin J Am Soc Nephrol 2013;8:1884-91. DOI PubMed PMC
86. Tesar V, Hruskova Z. Avacopan in the treatment of ANCA-associated vasculitis. Expert Opin Investig Drugs 2018;27:491-6. DOI
PubMed
87. Yuan J, Gou SJ, Huang J, Hao J, Chen M, Zhao MH. C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-
associated vasculitis. Arthritis Res Ther 2012;14:R140. DOI PubMed PMC
88. Gou SJ, Yuan J, Chen M, Yu F, Zhao MH. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-
associated vasculitis. Kidney Int 2013;83:129-37. DOI PubMed
89. Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Avacopan for the Treatment of ANCA-Associated
Vasculitis. N Engl J Med 2021;384:599-609. DOI PubMed
90. Manenti L, Vaglio A, Gnappi E, et al. Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with
outcomes among patients with ANCA-associated renal vasculitis. Clin J Am Soc Nephrol 2015;10:2143-51. DOI PubMed PMC